Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous, Allogenic), Cell & Tissue Banking), End User (Pharma & Biotech, Hospitals, Tissue Bank) - Global Forecast - ( 2022 - 2026 )
The global Stem Cell Manufacturing Market boasts a total value of $11.5 billion in 2021 and is projected to register a growth rate of 9.4% to reach a value of $18.0 billion by 2026. The two key factors driving the growth of the stem cell manufacturing market include, increase in traction for exploring therapeutic cabailitites of stem cell-based treatments and advent of novel technologies to scale up stem cell manufacturing. Increasing research in the fields of life sciences and biotechnology has led to the development of novel and innovative technologies for stem cell isolation, processing, and preservation. Key product manufacturers are developing advanced technologies and methodologies for stem cell manufacturing.
To know about the assumptions considered for the study, Request for Free Sample Report
Stem Cell Manufacturing Market Dynamics
Drivers: Increasing awareness about the therapeutic potency of stem cell products
Stem cell therapy is increasingly being recognized as a promising candidate in the field of regenerative medicine for the replacement or regeneration of damaged tissues. Due to the increasing awareness about the therapeutic efficacy of stem cell products, the demand for these products is increasing among various stakeholders. This is further supported by the growing number of clinical trials and successful research studies that utilize stem cell products for disease management and the validation of their therapeutic potential. In February 2021, ViaCyte (US) announced the initiation of a Phase II Study of Encapsulated Cell Therapy for Type I diabetes patients. The cell therapy is derived from pluripotent stem cells intended to replace insulin-producing pancreatic beta cells lost in Type I diabetes patients.
Restraints: Significant operational costs associated with stem cell manufacturing and banking
Stem cell isolation, purification, and storage require specialized techniques (such as expansion, differentiation, cell culture media preparation, and cryopreservation). Moreover, the manufacturing scale-up of stem cell lines and related accessories is often associated with significant technical difficulties that hinder the overall manufacturing process and amount to significant operational costs. Therefore, stem cell products are often priced at a premium as compared to pharmaceutical drugs and biologics.
Challenges: Technical limitations associated with manufacturing scale-up
Due to the technical complexities associated with various manufacturing stages, such as stem cell identification, isolation, storage, and preservation, it is extremely challenging for manufacturers to scale up their stem cell production competencies. In addition, several steps involved in the stem cell manufacturing process are still un-integrated and manual, which has a negative impact on the production capabilities of manufacturers. The scaling-up process is affected by the development process adopted during stem cell-based research.
Opportunities: Increased market focus on mesenchymal stem cells and induced pluripotent stem cells
Key players in the stem cell manufacturing market are increasingly focusing on developing mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) due to clinical evidence related to their therapeutic efficacy and safety profile. MSCs have the potential to form bone, cartilage, muscle, and adipose tissues, which in turn, have applications in several therapeutic areas. Also, as these cells do not need donor-recipient matching, MSCs can be made available off-the-shelf for immediate treatment. iPSCs are reprogrammed back to an embryonic stem cell-like state through the introduction of specific genes that are responsible for the maintenance of regenerative properties.
By product, the stem cell lines segment is the fastest growing segment in the stem cell manufacturing market.
Based on product, the stem cell manufacturing market is segmented into consumables, instruments and stem cell lines. The stem cell lines segment is the fastest growing segment in the stem cell manufacturing market. Market growth is mainly due to the growing demand for functionally potent stem cell lines in research; the rising approval of stem cell-based therapeutic products in the US, Europe, and Asia; and the development of innovative stem cell culture & preservation techniques.
By application, the clinical applications segment accounted for the second largest share of the stem cell manufacturing market in 2020.
Based on application, the stem cell manufacturing market is categorized into research applications, clinical application and cell & tissue banking applications. The demand for stem cell-based products in clinical applications is primarily driven by factors such as the increasing awareness regarding the therapeutic potency of stem cells in effective disease management, technological advancements in genome-based cell analysis and other technologies for stem cell manufacturing, and improving infrastructure related to stem cell processing and preservation.
By end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the stem cell manufacturing market in 2020.
Based on end users, the stem cell manufacturing market is segmented into pharmaceutical & biotechnology companies, academic institutes, research laboratories & contract research organizations, hospitals & surgical centers, cell banks & tissue banks and other end users. The pharmaceutical & biotechnology companies dominated the market in 2020. Pharmaceutical and biotechnology companies are major end users of stem cell products. These products are utilized for in-house clinical research and drug discovery programs. The demand for stem cell products among pharma-biotech companies is primarily driven by increasing private investments for stem cell-based research.
North America accounted for the largest share of the stem cell manufacturing market in 2020.
In 2020, North America accounted for the largest share of the stem cell manufacturing market, followed by Europe. Factors such as the robust research infrastructure in the region, rising public awareness related to the therapeutic potential of stem cells in effective disease management, and rising adoption of novel stem cell therapies in the US also support the growth of the stem cell manufacturing market in North America. However, stringent regulations related to ESCs and iPSC-based clinical research and strong market competition from alternative therapeutic technologies (such as gene therapy, drug-based treatment, and tissue & organ transplantation) are restraining this market.
Stem Cell Manufacturing Market Key Players
Thermo Fisher Scientific (US), Merck Milliopore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US) and Sartorius AG (Germany) are the prominent players operating in the stem cell manufacturing market.
Stem Cell Manufacturing Market Scope
|
Report Metric |
Details |
|
Market Size Available for Years |
2018–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Product, Application, End User and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
|
Companies Covered |
The major market players include Thermo Fisher Scientific (US), Merck Millipore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), Stemcell Technologies (Canada), Fujifilm Holdings Corporation (Japan), Miltenyi Biotec (Germany), Terumo BCT Inc. (US), Corning Inc. (US), Bio-Techne Corporation (US), Takara Bio Group (Japan), Eppendorf AG (Germany), Getinge (Sweden), Himedia Laboratories (India), Anterogen (South Korea), Cellgenix GMBH (Germany) and Promocell (Germany). |
The study categorizes the stem cell manufacturing market into the following segments and subsegments:
By Product
-
Consumables
- Culture Media
- Other Consumables
-
Instruments
- Bioreactors and Incubators
- Cell Sorters
- Other Instruments
-
Stem Cell Lines
- Hematopoietic stem cells (HSC)
- Mesenchymal stem cells (MSC)
- Induced Pluripotent Stem cells (iPSC)
- Embryonic stem cells (ESC)
- Neural Stem cells (NSC)
- Multipotent adult progenitor stem cells
By Application
-
Research Applications
- Life science research
- Drug discovery and development
-
Clinical Application
- Allogenic stem cell therapy
- Autologous stem cell therapy
- Cell & Tissue Banking Applications
By End User
- Pharmaceutical & Biotechnology Companies
- Academic institutes, Research laboratories & contract research organizations
- Hospitals & surgical centres
- Cell & tissue banks
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East and Africa
Recent Developments
- In January 2021, Thermo Fisher Scientific acquired Henogen S.A., Novasep's viral vector manufacturing business, to strengthen its capabilities for cell and gene vaccines and therapies globally.
- In November 2020, Lonza Group AG signed an agreement with FUJIFILM Cellular Dynamics. Under the agreement, Lonza granted FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector technology. Likewise, FUJIFILM Cellular Dynamics granted Lonza a non-exclusive right to use its patents related to iPSC generation. This will accelerate the development and manufacture of cell therapies.
- In March 2020, Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division and renamed it Cytiva.
- In October 2019, Thermo Fisher Scientific launched Gibco BenchStable Media, which remains stable at room temperature and reduces reliance on cold storage.
Frequently Asked Questions (FAQs):
What is the size of Stem Cell Manufacturing Market ?
The global Stem Cell Manufacturing Market is projected to reach USD 18.0 billion by 2026, growing at a CAGR of 9.4%.
What are the major growth factors of Stem Cell Manufacturing Market ?
The two key factors driving the growth of the stem cell manufacturing market include, increase in traction for exploring therapeutic cabailitites of stem cell-based treatments and advent of novel technologies to scale up stem cell manufacturing. Increasing research in the fields of life sciences and biotechnology has led to the development of novel and innovative technologies for stem cell isolation, processing, and preservation. Key product manufacturers are developing advanced technologies and methodologies for stem cell manufacturing.
Who all are the prominent players of Stem Cell Manufacturing Market ?
Thermo Fisher Scientific (US), Merck Milliopore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US) and Sartorius AG (Germany) are the prominent players operating in the stem cell manufacturing market. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 41)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 STEM CELL MANUFACTURING MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 45)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
FIGURE 3 STEM CELL MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
FIGURE 6 STEM CELL MANUFACTURING MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 STEM CELL MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 55)
FIGURE 9 STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 10 MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 11 MARKET, BY END USER 2021 VS. 2026 (USD MILLION)
FIGURE 12 GEOGRAPHICAL SNAPSHOT: STEM CELL MANUFACTURING MARKET
4 PREMIUM INSIGHTS (Page No. - 58)
4.1 STEM CELL MANUFACTURING MARKET OVERVIEW
FIGURE 13 GROWING INVESTMENTS IN STEM CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL MANUFACTURING MARKET SHARE, BY PRODUCT & COUNTRY (2020)
FIGURE 14 CONSUMABLES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN STEM CELL MANUFACTURING MARKET IN 2020
4.3 STEM CELL MANUFACTURING MARKET SHARE, BY END USER, 2020
FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
4.4 STEM CELL MANUFACTURING MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 RESEARCH APPLICATIONS WILL CONTINUE TO DOMINATE THE APPLICATIONS MARKET
4.5 STEM CELL MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE STEM CELL MANUFACTURING MARKET FROM 2021 TO 2026
5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 1 STEM CELL MANUFACTURING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing venture capital investments in stem cell research
5.2.1.2 Increasing awareness about the therapeutic potency of stem cell products
5.2.1.3 Technological advancements in stem cell manufacturing
5.2.1.4 Increasing incidence of cancer and collaborative efforts in cancer research
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
5.2.2 RESTRAINTS
5.2.2.1 Significant operational costs associated with stem cell manufacturing and banking
5.2.3 OPPORTUNITIES
5.2.3.1 Supportive regulatory framework across developing countries
5.2.3.2 Government initiatives to boost the biotechnology and biopharmaceutical industries
5.2.3.3 Increased market focus on mesenchymal stem cells and induced pluripotent stem cells
5.2.4 CHALLENGES
5.2.4.1 Technical limitations associated with manufacturing scale-up
5.2.4.2 Socio-ethical concerns related to the use of allogeneic and human embryonic stem cells
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE STEM CELL MANUFACTURING MARKET
5.3.1 INTRODUCTION
5.3.2 SUPPLY CHAIN
5.3.3 RESEARCH & DEVELOPMENT
FIGURE 18 CLINICAL TRIALS FOR COVID-19 USING STEM CELLS, BY REGION
5.3.4 RESEARCH FUNDING
5.4 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 STEM CELL MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.4.1 THREAT OF NEW ENTRANTS
5.4.2 THREAT OF SUBSTITUTES
5.4.3 BARGAINING POWER OF SUPPLIERS
5.4.4 BARGAINING POWER OF BUYERS
5.4.5 DEGREE OF COMPETITION
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF THE STEM CELL MANUFACTURING MARKET: RAW MATERIAL, MANUFACTURING, & ASSEMBLY PHASES ADD MAXIMUM VALUE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 STEM CELL MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 BIOREACTORS
TABLE 4 SINGLE-USE BIOREACTORS VS. STAINLESS-STEEL BIOREACTORS
5.7.2 CELL CULTURE MEDIA
5.7.3 CELL IMAGING SYSTEMS
5.8 ECOSYSTEM ANALYSIS
FIGURE 21 ECOSYSTEM ANALYSIS: STEM CELL MANUFACTURING MARKET
TABLE 5 ECOSYSTEM ANALYSIS
5.9 PATENT ANALYSIS
FIGURE 22 PATENT APPLICATIONS FOR STEM CELL MANUFACTURING, JANUARY 2010–DECEMBER 2020
5.10 PRICING ANALYSIS
TABLE 6 AVERAGE SELLING PRICE OF LAB-SCALE SINGLE-USE BIOREACTORS, BY REGION (2020)
TABLE 7 AVERAGE SELLING PRICE OF STEM CELL LINES (USD), BY REGION (2020)
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY ANALYSIS FOR STEM CELL MANUFACTURING PRODUCTS
5.11.1.1 North America
5.11.1.1.1 US
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.11.1.1.2 Canada
5.11.1.2 Europe
5.11.2 REGULATORY ANALYSIS FOR STEM CELL THERAPY PRODUCTS
5.11.2.1 US
5.11.2.2 European Union
6 STEM CELL MANUFACTURING MARKET, BY PRODUCT (Page No. - 82)
6.1 INTRODUCTION
TABLE 10 STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 CONSUMABLES
TABLE 11 MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 12 MARKET FOR CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 NORTH AMERICA: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 EUROPE: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 ASIA PACIFIC: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.1 CULTURE MEDIA
6.2.1.1 Rising stem cell research and increasing demand for stem cell therapies will contribute to the adoption of culture media
TABLE 16 STEM CELL MANUFACTURING MARKET FOR CULTURE MEDIA, BY REGION, 2019–2026 (USD MILLION)
TABLE 17 NORTH AMERICA: STEM CELL MANUFACTURING MARKET FOR CULTURE MEDIA, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 EUROPE: MARKET FOR CULTURE MEDIA, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 ASIA PACIFIC: MARKET FOR CULTURE MEDIA, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.2 OTHER CONSUMABLES
TABLE 20 MARKET FOR OTHER CONSUMABLES, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 NORTH AMERICA: MARKET FOR OTHER CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 EUROPE: MARKET FOR OTHER CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 ASIA PACIFIC: MARKET FOR OTHER CONSUMABLES, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 24 STEM CELL MANUFACTURING MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 25 MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 EUROPE: MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.1 BIOREACTORS & INCUBATORS
6.3.1.1 The introduction of advanced bioreactors and incubators is contributing to market growth
TABLE 29 STEM CELL MANUFACTURING MARKET FOR BIOREACTORS & INCUBATORS, BY REGION, 2019–2026 (USD MILLION)
TABLE 30 NORTH AMERICA: STEM CELL MANUFACTURING MARKET FOR BIOREACTORS & INCUBATORS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 31 EUROPE: STEM CELL MANUFACTURING MARKET FOR BIOREACTORS & INCUBATORS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 ASIA PACIFIC: STEM CELL MANUFACTURING MARKET FOR BIOREACTORS & INCUBATORS, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.2 CELL SORTERS
6.3.2.1 Growth can be attributed to the development of novel cell sorting technologies such as microfluidics
TABLE 33 STEM CELL MANUFACTURING MARKET FOR CELL SORTERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 34 NORTH AMERICA: MARKET FOR CELL SORTERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 EUROPE: MARKET FOR CELL SORTERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 ASIA PACIFIC: MARKET FOR CELL SORTERS, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.3 OTHER INSTRUMENTS
TABLE 37 MARKET FOR OTHER INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 EUROPE: MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 ASIA PACIFIC: MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 STEM CELL LINES
TABLE 41 STEM CELL MANUFACTURING MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 42 MARKET FOR STEM CELL LINES, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET FOR STEM CELL LINES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 EUROPE: MARKET FOR STEM CELL LINES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 ASIA PACIFIC: MARKET FOR STEM CELL LINES, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.1 HEMATOPOIETIC STEM CELLS
6.4.1.1 Growth is driven by the increasing adoption of cord blood banking
TABLE 46 HEMATOPOIETIC STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: HEMATOPOIETIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 48 EUROPE: HEMATOPOIETIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 ASIA PACIFIC: HEMATOPOIETIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.2 MESENCHYMAL STEM CELLS
6.4.2.1 Ease of cell harvesting, processing, and preservation drives the adoption of MSCs
TABLE 50 MESENCHYMAL STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 EUROPE: MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 ASIA PACIFIC: MESENCHYMAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.3 INDUCED PLURIPOTENT STEM CELLS
6.4.3.1 Growth can be attributed to the increased adoption of iPSCs in research on cell therapies & regenerative medicine
TABLE 54 INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 55 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.4 EMBRYONIC STEM CELLS
6.4.4.1 Rising research activity in cancer precision medicine contributes to segmental growth
TABLE 58 EMBRYONIC STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 59 NORTH AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 60 EUROPE: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 ASIA PACIFIC: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.5 NEURAL STEM CELLS
6.4.5.1 The introduction of novel isolation and expansion techniques for NSCs will drive the market
TABLE 62 NEURAL STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: NEURAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 EUROPE: NEURAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 65 ASIA PACIFIC: NEURAL STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.6 MULTIPOTENT ADULT PROGENITOR STEM CELLS
6.4.6.1 Rising awareness of the role of MAPCs in research
TABLE 66 MULTIPOTENT ADULT PROGENITOR STEM CELLS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: MULTIPOTENT ADULT PROGENITOR STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 EUROPE: MULTIPOTENT ADULT PROGENITOR STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 69 ASIA PACIFIC: MULTIPOTENT ADULT PROGENITOR STEM CELLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 STEM CELL MANUFACTURING MARKET, BY APPLICATION (Page No. - 111)
7.1 INTRODUCTION
TABLE 70 STEM CELL MANUFACTURING MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 RESEARCH APPLICATIONS
TABLE 71 MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.1 LIFE SCIENCE RESEARCH
7.2.1.1 Market growth is driven by the increasing research focus on stem cell cytology & pathology
TABLE 76 MARKET FOR LIFE SCIENCE RESEARCH, BY REGION, 2019–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR LIFE SCIENCE RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR LIFE SCIENCE RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 79 ASIA PACIFIC: STEM CELL MANUFACTURING MARKET FOR LIFE SCIENCE RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.2 DRUG DISCOVERY & DEVELOPMENT
7.2.2.1 Increasing research expenditure by pharma and biotech companies will contribute to market growth
TABLE 80 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 CLINICAL APPLICATIONS
TABLE 84 MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1 ALLOGENEIC STEM CELL THERAPY
7.3.1.1 Wide therapeutic applications of stem cell lines to drive growth
TABLE 89 MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY REGION, 2019–2026 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 AUTOLOGOUS STEM CELL THERAPY
7.3.2.1 Increasing patient preference for autologous stem cell therapy will drive segmental growth
TABLE 93 MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2019–2026 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 CELL & TISSUE BANKING APPLICATIONS
7.4.1 RISING DEMAND FOR CORD BLOOD STEM CELL BANKING INDICATES FAVORABLE PROSPECTS
TABLE 97 MARKET FOR CELL & TISSUE BANKING APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET FOR CELL & TISSUE BANKING APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 EUROPE: MARKET FOR CELL & TISSUE BANKING APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET FOR CELL & TISSUE BANKING APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
8 MARKET, BY END USER (Page No. - 127)
8.1 INTRODUCTION
TABLE 101 STEM CELL MANUFACTURING MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 GROWTH IS DRIVEN BY INCREASING PRIVATE INVESTMENTS FOR STEM CELL-BASED RESEARCH
TABLE 102 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 104 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 ACADEMIC INSTITUTES, RESEARCH LABORATORIES, AND CONTRACT RESEARCH ORGANIZATIONS
8.3.1 MARKET GROWTH IS DRIVEN BY INCREASED PUBLIC FUNDING FOR RESEARCH ACTIVITIES
TABLE 106 MARKET FOR ACADEMIC INSTITUTES, RESEARCH LABORATORIES, AND CROS, BY REGION, 2019–2026 (USD MILLION)
TABLE 107 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, RESEARCH LABORATORIES, AND CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 108 EUROPE: MARKET FOR ACADEMIC INSTITUTES, RESEARCH LABORATORIES, AND CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 109 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, RESEARCH LABORATORIES, AND CROS, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 HOSPITALS & SURGICAL CENTERS
8.4.1 GROWTH CAN BE ATTRIBUTED TO IMPROVED HEALTHCARE INFRASTRUCTURE
TABLE 110 MARKET FOR HOSPITALS & SURGICAL CENTERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 111 NORTH AMERICA: MARKET FOR HOSPITALS & SURGICAL CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 112 EUROPE: MARKET FOR HOSPITALS & SURGICAL CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 113 ASIA PACIFIC: MARKET FOR HOSPITALS & SURGICAL CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 CELL & TISSUE BANKS
8.5.1 GROWING APPLICATION OF STEM CELLS IN DISEASE TREATMENT WILL DRIVE MARKET GROWTH
TABLE 114 MARKET FOR CELL & TISSUE BANKS, BY REGION, 2019–2026 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR CELL & TISSUE BANKS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR CELL & TISSUE BANKS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR CELL & TISSUE BANKS, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 OTHER END USERS
TABLE 118 MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 119 NORTH AMERICA: STEM CELL MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 120 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 121 ASIA PACIFIC: STEM CELL MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
9 MARKET, BY REGION (Page No. - 139)
9.1 INTRODUCTION
TABLE 122 MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: MARKET SNAPSHOT
TABLE 123 NORTH AMERICA: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 124 NORTH AMERICA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 NORTH AMERICA: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 128 NORTH AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 NORTH AMERICA: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 131 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 Continued focus to strengthen R&D to drive the market in the US
TABLE 132 US: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 133 US: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 134 US: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 US: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 137 US: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 US: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising government investment to drive the market in Canada
TABLE 140 CANADA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 141 CANADA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 CANADA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 143 CANADA: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 145 CANADA: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 146 CANADA: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 148 EUROPE: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 149 EUROPE: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 EUROPE: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 151 EUROPE: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 152 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 153 EUROPE: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 154 EUROPE: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 156 EUROPE: STEM CELL MANUFACTURING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Strong growth in the biotechnology industry to drive market growth in the country
TABLE 157 GERMANY: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 158 GERMANY: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 GERMANY: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 GERMANY: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 162 GERMANY: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 GERMANY: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Government support in stem cell manufacturing to drive the market
TABLE 165 FRANCE: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 166 FRANCE: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 167 FRANCE: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 168 FRANCE: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 169 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 170 FRANCE: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 171 FRANCE: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 UK
9.3.3.1 Focus on innovation will increase demand for stem-cell-based therapeutics
TABLE 173 UK: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 174 UK: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 175 UK: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 UK: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 178 UK: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 179 UK: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 180 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Initiatives encouraging the development of cell and gene therapy to boost the demand for stem cell manufacturing in the country
TABLE 181 ITALY: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 182 ITALY: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 ITALY: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 ITALY: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 ITALY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 186 ITALY: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 ITALY: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
" TABLE 188 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION) "
9.3.5 SPAIN
9.3.5.1 Increasing funding from private and public organizations to drive the growth of the market in Spain
TABLE 189 SPAIN: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 190 SPAIN: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 191 SPAIN: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 SPAIN: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 SPAIN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 194 SPAIN: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 SPAIN: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 ROE
TABLE 197 ROE: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 198 ROE: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 ROE: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 200 ROE: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 202 ROE: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 203 ROE: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: STEM CELL MANUFACTURING MARKET SNAPSHOT
TABLE 205 APAC: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 206 APAC: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 APAC: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 208 APAC: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 APAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 210 APAC: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 APAC: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 APAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 213 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Increasing clinical trials for stem cells and innovations to drive the market
TABLE 214 CHINA: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 215 CHINA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 CHINA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 CHINA: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 219 CHINA: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 CHINA: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Growing collaborations for stem cell research to drive the growth of the market in the country
TABLE 222 JAPAN: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 223 JAPAN: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 JAPAN: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 225 JAPAN: STEM CELL MANUFACTURING MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 JAPAN: STEM CELL MANUFACTURING MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 227 JAPAN: STEM CELL MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 JAPAN: STEM CELL MANUFACTURING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 JAPAN: STEM CELL MANUFACTURING MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 The growing prevalence of chronic diseases and focus on stem cell research would drive demand in the country
TABLE 230 INDIA: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 231 INDIA: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 INDIA: STEM CELL MANUFACTURING MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 INDIA: STEM CELL MANUFACTURING MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 234 INDIA: STEM CELL MANUFACTURING MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 235 INDIA: STEM CELL MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 236 INDIA: STEM CELL MANUFACTURING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 INDIA: STEM CELL MANUFACTURING MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 238 ROAPAC: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 239 ROAPAC: STEM CELL MANUFACTURING MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ROAPAC: STEM CELL MANUFACTURING MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 241 ROAPAC: STEM CELL MANUFACTURING MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 242 ROAPAC: STEM CELL MANUFACTURING MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 243 ROAPAC: STEM CELL MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 244 ROAPAC: STEM CELL MANUFACTURING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 245 ROAPAC: STEM CELL MANUFACTURING MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 GROWING PHARMACEUTICAL INDUSTRY IN THE REGION PROJECTED TO DRIVE THE MARKET GROWTH
TABLE 246 LATIN AMERICA: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 247 LATIN AMERICA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 248 LATIN AMERICA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 249 LATIN AMERICA: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 251 LATIN AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 LATIN AMERICA: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 253 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 INCREASING FUNDING AND COLLABORATIONS TO DRIVE MARKET GROWTH IN THE REGION
TABLE 254 MEA: STEM CELL MANUFACTURING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 255 MEA: MARKET FOR CONSUMABLES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 256 MEA: MARKET FOR INSTRUMENTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 257 MEA: MARKET FOR STEM CELL LINES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 258 MEA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 259 MEA: MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 260 MEA: MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 MEA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 201)
10.1 OVERVIEW
10.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
FIGURE 25 KEY PLAYER STRATEGIES IN THE STEM CELL MANUFACTURING MARKET, 2018– 2021
10.3 MARKET SHARE ANALYSIS
FIGURE 26 STEM CELL MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 EMERGING COMPANIES
FIGURE 28 STEM CELL MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2020
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 29 STEM CELL MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
10.7 PRODUCT FOOTPRINT OF COMPANIES
TABLE 262 PRODUCT PORTFOLIO ANALYSIS: STEM CELL MANUFACTURING MARKET (2020)
10.8 GEOGRAPHIC FOOTPRINT OF COMPANIES
TABLE 263 GEOGRAPHIC FOOTPRINT: STEM CELL MANUFACTURING MARKET (2020)
10.9 MARKET EVALUATION FRAMEWORK
TABLE 264 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS—THE MAJOR STRATEGIES ADOPTED BY PLAYERS
10.10 COMPETITIVE SCENARIO
10.10.1 STEM CELL MANUFACTURING MARKET: PRODUCT LAUNCHES, JANUARY 2018–APRIL 2021
10.10.2 STEM CELL MANUFACTURING MARKET: DEALS, JANUARY 2018–APRIL 2021
10.10.3 STEM CELL MANUFACTURING MARKET: EXPANSIONS, JANUARY 2018–
11 COMPANY PROFILES (Page No. - 213)
11.1 KEY MARKET PLAYERS
(Introduction, Products offered, Recent developments, SWOT analysis, MNM view)*
11.1.1 THERMO FISHER SCIENTIFIC
TABLE 265 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 30 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
TABLE 266 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
11.1.2 MERCK MILLIPORE
TABLE 267 MERCK MILLIPORE: BUSINESS OVERVIEW
FIGURE 31 MERCK MILLIPORE: COMPANY SNAPSHOT (2020)
TABLE 268 MERCK MILLIPORE: PRODUCTS OFFERED
11.1.3 LONZA GROUP
TABLE 269 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 32 LONZA GROUP AG: COMPANY SNAPSHOT (2020)
TABLE 270 LONZA GROUP: PRODUCTS OFFERED
11.1.4 DANAHER CORPORATION
TABLE 271 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
TABLE 272 DANAHER CORPORATION: PRODUCTS OFFERED
11.1.5 SARTORIUS AG
TABLE 273 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 34 SARTORIUS AG: COMPANY SNAPSHOT (2020)
TABLE 274 SARTORIUS AG: PRODUCTS OFFERED
11.1.6 BECTON, DICKINSON AND COMPANY
TABLE 275 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
TABLE 276 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
11.1.7 EPPENDORF AG
TABLE 277 EPPENDORF AG: BUSINESS OVERVIEW
FIGURE 36 EPPENDORF AG: COMPANY SNAPSHOT (2019)
TABLE 278 EPPENDORF AG: PRODUCTS OFFERED
11.1.8 CORNING INC.
TABLE 279 CORNING INC.: BUSINESS OVERVIEW
FIGURE 37 CORNING INC.: COMPANY SNAPSHOT (2020)
TABLE 280 CORNING INC.: PRODUCTS OFFERED
11.1.9 BIO-RAD LABORATORIES
TABLE 281 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 38 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
TABLE 282 BIO-RAD LABORATORIES: PRODUCTS OFFERED
11.1.10 TAKARA BIO GROUP
TABLE 283 TAKARA BIO GROUP: BUSINESS OVERVIEW
FIGURE 39 TAKARA BIO GROUP: COMPANY SNAPSHOT (2020)
TABLE 284 TAKARA BIO GROUP: PRODUCTS OFFERED
11.1.11 FUJIFILM HOLDINGS CORPORATION
TABLE 285 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 40 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
TABLE 286 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
11.1.12 GETINGE AB
TABLE 287 GETINGE AB: BUSINESS OVERVIEW
FIGURE 41 GETINGE AB: COMPANY SNAPSHOT (2020)
TABLE 288 GETINGE AB: PRODUCTS OFFERED
11.1.13 TERUMO CORPORATION
TABLE 289 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 42 TERUMO CORPORATION: COMPANY SNAPSHOT (2020)
TABLE 290 TERUMO CORPORATION: PRODUCTS OFFERED
11.1.14 BIO-TECHNE CORPORATION
TABLE 291 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
TABLE 292 BIO-TECHNE CORPORATION: PRODUCTS OFFERED
11.1.15 HIMEDIA LABORATORIES
TABLE 293 HIMEDIA LABORATORIES: BUSINESS OVERVIEW
TABLE 294 HIMEDIA LABORATORIES: PRODUCTS OFFERED
11.2 OTHER PLAYERS
11.2.1 STEMCELL TECHNOLOGIES INC.
TABLE 295 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
TABLE 296 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
11.2.2 MILTENYI BIOTEC GMBH
TABLE 297 MILTENYI BIOTEC GMBH: BUSINESS OVERVIEW
TABLE 298 MILTENYI BIOTEC GMBH: PRODUCTS OFFERED
11.2.3 PROMOCELL
TABLE 299 PROMOCELL: BUSINESS OVERVIEW
TABLE 300 PROMOCELL: PRODUCTS OFFERED
11.2.4 ANTEROGEN CO., LTD.
TABLE 301 ANTEROGEN: BUSINESS OVERVIEW
TABLE 302 ANTEROGEN: PRODUCTS OFFERED
11.2.5 CELLGENIX GMBH
TABLE 303 CELLGENIX GMBH: BUSINESS OVERVIEW
TABLE 304 CELLGENIX GMBH: PRODUCTS OFFERED
*Introduction, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 289)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global stem cell manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the stem cell manufacturing market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary DATA
The secondary sources referred to for this research study include publications from government and international sources, such as the World Health Organisation (WHO), National Institutes of Health (NIH), International Society for Stem Cell Research (ISSCR), International Stem Cell Forum (ISCF), International Society for Cellular Therapy (ISCT), International Consortium of Stem Cell Networks (ICSCN), EuroStemCell, European Society of Gene and Cell Therapy, German Stem Cell Network, Japan Human Cell Society, Chinese Stem Cell Foundation, Brazilian Association of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global stem cell manufacturing market, which was validated through primary research.
Primary DATA
Extensive primary research was conducted after acquiring basic knowledge about the global stem cell manufacturing market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biotechnology companies, academic institutes & research centers, and cell banks) and supply-side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others from tier 1 and tier 2 companies engaged in offering product in stem cell manufacturing market) across five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Primary research was used in this report to:
- Validate the market segmentation defined through a product portfolio assessment of the leading players in the stem cell manufacturing market
- Understand key industry trends and issues defining the strategic growth objectives of market players
- Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, restraints, and opportunities)
- Validate assumptions for the market sizing and forecasting model used for this study
- Understand the market position of leading players in the stem cell manufacturing market and their market shares/rankings
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the stem cell manufacturing market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the stem cell manufacturing market.
Report Objectives
- To define, describe, and forecast the global stem cell manufacturing market based on product, application, end-user, and region.
- To provide detailed information on the major factors influencing the market growth (such as drivers, restraints, and opportunities).
- To strategically analyze micromarkets in terms of individual growth trends, future prospects, and contributions to the overall stem cell manufacturing market.
- To analyze opportunities in the global market for major stakeholders and provide a detailed competitive landscape for market leaders.
- To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
- To profile the key players and comprehensively analyze their market shares and core competencies.
- To track and analyze competitive developments such as new product launches; acquisitions; expansions; and partnerships, collaborations, and agreements.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe stem cell manufacturing market into respective countries.
- Further breakdown of the Rest of Asia Pacific stem cell manufacturing market into respective countries.
- Further breakdown of the Latin American and the MEA stem cell manufacturing market into respective countries.
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Growth opportunities and latent adjacency in Stem Cell Manufacturing Market
Which segment accounted for the largest market share for the stem cell manufacturing market?
I want to know about the key players in stem cell manufacturing.